| NAME | ORIGINATOR | INDICATION | DEVELOPMENT STATUS |
| CYSTADROPS® | Recordati | Corneal cysteine crystal deposits in patients with cystinosis | Development of new formulation in EU and USA |
| FORTACIN TM | Plethora Solutions | Premature ejaculation | Post-marketing |
| REAGILA® | Gedeon Richter | Schizophrenia | Pediatric post-approval development plan |
| methadone | Treatment of cancer-related pain in cases of resistance or intolerance to opioids | Approved in France Market access activities underway |
|
| CARBAGLU® | Recordati | Hyperammonaemia due to NAGS deficiency and to the main organic acidemias | Development of new formulations in EU and USA Filed in the USA for the organic acidemias indication |
| REC 0551 | Recordati/Meyer Hospital (Florence) | Retinopathy of Prematurity (ROP) | Formulation development Phase II in Italy |
| REC 0438 | Recordati/UFPeptides | Overactive bladder in patients with spinal lesions | Proof of concept trial planning in EU |
| REC 0559 | Recordati/Mime Tech | Neurotrophic keratitis | Formulation development Clinical development planning |
| REC 0545 | Recordati/AP-HP | Acute decompensation episodes in MSUD | Formulation development. Retrospective study in France and Germany |